Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts
Parkinson’s Disease (PD) is characterized both by the loss of dopaminergic neurons in the substantia nigra and the presence of cytoplasmic inclusions called Lewy Bodies. These Lewy Bodies contain the aggregated α-synuclein (α-syn) protein, which has been shown to be able...
Main Authors: | Margaux Teil, Marie-Laure Arotcarena, Emilie Faggiani, Florent Laferriere, Erwan Bezard, Benjamin Dehay |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/3/391 |
Similar Items
-
Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery
by: Marie-Laure Arotcarena, et al.
Published: (2019-06-01) -
A New Rise of Non-Human Primate Models of Synucleinopathies
by: Margaux Teil, et al.
Published: (2021-03-01) -
Editorial: The Protein Alpha-Synuclein: Its Normal Role (in Neurons) and Its Role in Disease
by: Ruth G. Perez
Published: (2020-02-01) -
Alpha-Synuclein spreading in Parkinson disease
by: Ariadna eRecasens, et al.
Published: (2014-12-01) -
Seeking a Mechanism for the Toxicity of Oligomeric α-Synuclein
by: Hazel L. Roberts, et al.
Published: (2015-03-01)